Kyle Groom, DO
Family Medicine · de Kalb, TXNPI 1063413656
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 105 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $421 and has fallen 52.0% since, to $202 in 2025.
Across 105 payments — averaging $16.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$285
- GSK$280
- Pfizer$183
- Lilly USA, LLC$159
- AstraZeneca$156
- Novo Nordisk$106
- plus $517 from 13 others
Across 4 payments — averaging $16,769 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ortho-clinical Diagnostics, Inc.$67K
What the payments were for
- Food & beverage$1,686100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 20 | $285 |
| GSK | 17 | $280 |
| Pfizer | 11 | $183 |
| Lilly USA, LLC | 11 | $159 |
| AstraZeneca | 11 | $156 |
| Novo Nordisk | 7 | $106 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $91 |
| Abbott | 4 | $88 |
| Novartis | 4 | $62 |
| Genentech USA, Inc. | 3 | $52 |
| Mylan Specialty L.p. | 3 | $48 |
| Almatica Pharma LLC | 2 | $41 |
| Merck | 2 | $30 |
| Acadia Pharmaceuticals Inc | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
How this compares
$1,686 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 19 | $622 |
| Quetiapine Fumarate | 12 | $368 |
| Potassium Chloride | 19 | $285 |
| Azithromycin | 38 | $283 |
| Clindamycin Hcl | 25 | $221 |
| Ondansetron OdtOndansetron | 16 | $215 |
| Levothyroxine Sodium | 30 | $188 |
| Losartan Potassium | 15 | $180 |
| Cefdinir | 11 | $180 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 18 | $165 |
| Tramadol Hcl | 16 | $114 |
| Alprazolam | 13 | $95 |
| Gabapentin | 12 | $88 |
| Atorvastatin Calcium | 18 | $78 |
| Ciprofloxacin Hcl | 14 | $72 |
Paid to pharmacies, not to this prescriber.
Other family medicine in de Kalb
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
- Jose LedezmaEdinburg$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.